10 Low Risk High Reward Stocks Set to Triple by 2030

2. Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Number of Hedge Fund Holders: 36

Potential upside: 301.12%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) focuses on creating targeted cancer treatments, especially for kids and young adults. This clinical-stage biopharma company develops therapies for patients with genetic cancer markers. Specializing in pediatric and young cancer treatments, Day One has a promising front in bringing these treatments to market.

The year 2024 was successful for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN). The FDA authorized OJEMDA for treating relapsed or resistant pediatric low-grade glioma (pLGG). The drug took off fast, bringing in $57 million in just eight months, with $29 million in the fourth quarter alone (up 44% from Q3). The company logged over 1,600 prescriptions, with 280 patients actively using the therapy by year-end.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) grew by expanding into priority medical centers and scoring a favorable CMS designation that boosted its profit margins. Furthermore, the prescriptions doubled in Q4 compared to the previous six months combined, showing the increasing demand.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) keeps building its pipeline further with its Phase III FIREFLY-2 trial for frontline pLGG treatment expanding worldwide, aiming to finish enrollment by mid-2026. In addition, it has also started testing DAY301, a new antibody-drug that targets PTK7. The drug is in Phase Ia/b dose escalation trials, meanwhile, the company struck a licensing deal with Ipsen to sell OJEMDA outside the U.S.

On the financial end, Day One is well-positioned with over $500 million in cash, giving it plenty of runway without a need to raise funds soon. Its solid finances, consistent execution, and promising drug candidates make Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) potentially one of the best low risk stocks for investors interested in cutting-edge cancer treatments.